LENZ THERAPEUTICS INC (LENZ) Fundamental Analysis & Valuation

NASDAQ:LENZ • US52635N1037

13.18 USD
+0.03 (+0.23%)
Last: Mar 4, 2026, 09:48 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LENZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, LENZ scores 3 out of 10 in our fundamental rating. LENZ was compared to 193 industry peers in the Pharmaceuticals industry. While LENZ has a great health rating, there are worries on its profitability. LENZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. LENZ Profitability Analysis

1.1 Basic Checks

  • In the past year LENZ has reported negative net income.
  • In the past year LENZ has reported a negative cash flow from operations.
  • LENZ had negative earnings in each of the past 5 years.
  • In the past 5 years LENZ always reported negative operating cash flow.
LENZ Yearly Net Income VS EBIT VS OCF VS FCFLENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • LENZ has a Return On Assets (-24.11%) which is comparable to the rest of the industry.
  • With a decent Return On Equity value of -25.39%, LENZ is doing good in the industry, outperforming 66.32% of the companies in the same industry.
Industry RankSector Rank
ROA -24.11%
ROE -25.39%
ROIC N/A
ROA(3y)-40.22%
ROA(5y)-88.15%
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LENZ Yearly ROA, ROE, ROICLENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LENZ Yearly Profit, Operating, Gross MarginsLENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. LENZ Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for LENZ has been increased compared to 1 year ago.
  • LENZ has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for LENZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LENZ Yearly Shares OutstandingLENZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
LENZ Yearly Total Debt VS Total AssetsLENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 21.59 indicates that LENZ is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 21.59, LENZ belongs to the top of the industry, outperforming 89.12% of the companies in the same industry.
  • LENZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.59
ROIC/WACCN/A
WACCN/A
LENZ Yearly LT Debt VS Equity VS FCFLENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 20.54 indicates that LENZ has no problem at all paying its short term obligations.
  • The Current ratio of LENZ (20.54) is better than 90.67% of its industry peers.
  • A Quick Ratio of 20.54 indicates that LENZ has no problem at all paying its short term obligations.
  • LENZ's Quick ratio of 20.54 is amongst the best of the industry. LENZ outperforms 90.67% of its industry peers.
Industry RankSector Rank
Current Ratio 20.54
Quick Ratio 20.54
LENZ Yearly Current Assets VS Current LiabilitesLENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LENZ Growth Analysis

3.1 Past

  • LENZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.60%, which is quite impressive.
EPS 1Y (TTM)70.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LENZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.09% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.37%
EPS Next 2Y16.98%
EPS Next 3Y22.36%
EPS Next 5Y23.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LENZ Yearly Revenue VS EstimatesLENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
LENZ Yearly EPS VS EstimatesLENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. LENZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LENZ. In the last year negative earnings were reported.
  • Also next year LENZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LENZ Price Earnings VS Forward Price EarningsLENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LENZ Per share dataLENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • LENZ's earnings are expected to grow with 22.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.98%
EPS Next 3Y22.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LENZ Dividend Analysis

5.1 Amount

  • No dividends for LENZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LENZ Fundamentals: All Metrics, Ratios and Statistics

LENZ THERAPEUTICS INC

NASDAQ:LENZ (3/4/2026, 9:48:48 AM)

13.18

+0.03 (+0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-25
Inst Owners103.35%
Inst Owner Change18.5%
Ins Owners2.52%
Ins Owner Change-17.29%
Market Cap412.40M
Revenue(TTM)17.50M
Net Income(TTM)-52.40M
Analysts87.69
Price Target51.17 (288.24%)
Short Float %27.65%
Short Ratio8.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.07%
Min EPS beat(2)6.09%
Max EPS beat(2)18.05%
EPS beat(4)3
Avg EPS beat(4)8.72%
Min EPS beat(4)-9.11%
Max EPS beat(4)19.83%
EPS beat(8)4
Avg EPS beat(8)-64.09%
EPS beat(12)6
Avg EPS beat(12)-61.1%
EPS beat(16)8
Avg EPS beat(16)-47.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.35%
PT rev (3m)-4.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)11.12%
Revenue NY rev (3m)48.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.48
P/FCF N/A
P/OCF N/A
P/B 2
P/tB 2
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.16
BVpS6.6
TBVpS6.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.11%
ROE -25.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.22%
ROA(5y)-88.15%
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 761.11%
Cap/Sales 13.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.54
Quick Ratio 20.54
Altman-Z 21.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)512.78%
Cap/Depr(5y)723.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.26%
EPS Next Y43.37%
EPS Next 2Y16.98%
EPS Next 3Y22.36%
EPS Next 5Y23.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.39%
EBIT Next 3Y11.23%
EBIT Next 5YN/A
FCF growth 1Y45.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.52%
OCF growth 3YN/A
OCF growth 5YN/A

LENZ THERAPEUTICS INC / LENZ FAQ

Can you provide the ChartMill fundamental rating for LENZ THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to LENZ.


Can you provide the valuation status for LENZ THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to LENZ THERAPEUTICS INC (LENZ). This can be considered as Overvalued.


Can you provide the profitability details for LENZ THERAPEUTICS INC?

LENZ THERAPEUTICS INC (LENZ) has a profitability rating of 1 / 10.